Can radiation-recall predict long lasting response to immune checkpoint inhibitors?

Abstract

RR secondary to ICI (nivolumab in all patients) were observed in the lung (n = 1) or skin (n = 3). All patients had a long-term response to ICI and are currently alive with no active disease (Median FU from ICI discontinuation: 30 months). RR could reflect a beneficial immune activation and constitute a predictive clinical biomarker of ICI long-term efficacy.

Keywords: Anti CTLA4; Anti PD-L1; Anti-PD1; Radioimmunotherapy.